Department of Respiratory and Critical Care Medicine, Binzhou Medical University Hospital, Binzhou, China.
The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.
Am J Gastroenterol. 2020 May;115(5):766-773. doi: 10.14309/ajg.0000000000000620.
Since the outbreak of Coronavirus Disease 2019 (COVID-19) in December 2019, various digestive symptoms have been frequently reported in patients infected with the virus. In this study, we aimed to further investigate the prevalence and outcomes of COVID-19 patients with digestive symptoms.
In this descriptive, cross-sectional, multicenter study, we enrolled confirmed patients with COVID-19 who presented to 3 hospitals from January 18, 2020, to February 28, 2020. All patients were confirmed by real-time polymerase chain reaction and were analyzed for clinical characteristics, laboratory data, and treatment. Data were followed up until March 18, 2020.
In the present study, 204 patients with COVID-19 and full laboratory, imaging, and historical data were analyzed. The average age was 52.9 years (SD ± 16), including 107 men and 97 women. Although most patients presented to the hospital with fever or respiratory symptoms, we found that 103 patients (50.5%) reported a digestive symptom, including lack of appetite (81 [78.6%] cases), diarrhea (35 [34%] cases), vomiting (4 [3.9%] cases), and abdominal pain (2 [1.9%] cases). If lack of appetite is excluded from the analysis (because it is less specific for the gastrointestinal tract), there were 38 total cases (18.6%) where patients presented with a gastrointestinal-specific symptom, including diarrhea, vomiting, or abdominal pain. Patients with digestive symptoms had a significantly longer time from onset to admission than patients without digestive symptoms (9.0 days vs 7.3 days). In 6 cases, there were digestive symptoms, but no respiratory symptoms. As the severity of the disease increased, digestive symptoms became more pronounced. Patients with digestive symptoms had higher mean liver enzyme levels, lower monocyte count, longer prothrombin time, and received more antimicrobial treatment than those without digestive symptoms.
We found that digestive symptoms are common in patients with COVID-19. Moreover, these patients have a longer time from onset to admission, evidence of longer coagulation, and higher liver enzyme levels. Clinicians should recognize that digestive symptoms, such as diarrhea, are commonly among the presenting features of COVID-19 and that the index of suspicion may need to be raised earlier in at-risk patients presenting with digestive symptoms. However, further large sample studies are needed to confirm these findings.
自 2019 年 12 月爆发 2019 年冠状病毒病(COVID-19)以来,感染该病毒的患者常出现各种消化系统症状。本研究旨在进一步调查 COVID-19 患者伴发消化系统症状的患病率和结局。
本研究为描述性、横断面、多中心研究,共纳入 2020 年 1 月 18 日至 2 月 28 日期间来自 3 家医院的确诊 COVID-19 患者。所有患者均通过实时聚合酶链反应确诊,并对其临床特征、实验室数据和治疗进行分析。数据随访至 2020 年 3 月 18 日。
本研究共分析了 204 例 COVID-19 患者的完整实验室、影像学和病史资料。患者平均年龄为 52.9 岁(标准差 ± 16),包括 107 名男性和 97 名女性。尽管大多数患者以发热或呼吸道症状就诊,但我们发现 103 例(50.5%)患者报告存在消化系统症状,包括食欲不振(81 例[78.6%])、腹泻(35 例[34%])、呕吐(4 例[3.9%])和腹痛(2 例[1.9%])。如果将分析中排除食欲不振(因为它对胃肠道的特异性较低),则有 38 例(18.6%)患者出现胃肠道特异性症状,包括腹泻、呕吐或腹痛。有消化系统症状的患者从发病到入院的时间明显长于无消化系统症状的患者(9.0 天比 7.3 天)。在 6 例患者中,存在消化系统症状但无呼吸道症状。随着疾病严重程度的增加,消化系统症状变得更加明显。有消化系统症状的患者的平均肝酶水平较高,单核细胞计数较低,凝血酶原时间较长,且比无消化系统症状的患者接受更多的抗菌治疗。
我们发现 COVID-19 患者常出现消化系统症状。此外,这些患者的发病至入院时间较长,凝血时间延长,肝酶水平升高。临床医生应认识到,腹泻等消化系统症状通常是 COVID-19 的首发特征之一,因此对有消化系统症状的高危患者,其可疑指数可能需要更早提高。但仍需要进一步的大样本研究来证实这些发现。